Drug Profile
Naldemedine - Shionogi
Alternative Names: Rizmoic; S-297995; SymproicLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Purdue Pharma; Shionogi
- Class Antiemetics; Laxatives; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Constipation
- Discontinued Postoperative ileus
Most Recent Events
- 04 Oct 2022 Discontinued - Phase-II for Postoperative ileus (In the elderly, In adults) in USA (PO)
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 04 Jan 2021 Shionogi terminates a phase-II clinical trial in Postoperative ileus (In the elderly, In adults) due to slow patient enrollments, in USA (PO) (NCT04355169)